Customer Education

Beyond Cel-I Webinar


 What Does it Cover?

Gene editing has become a firmly established technology within the discovery sciences arena.  With the advent of CRISPR/Cas9 systems, the researcher's ability to find an active nuclease for nearly any region of any genome is now a reality. Even with better nucleases available, those who routinely use gene editing tools to manipulate cell lines encounter other significant challenges that pose a barrier to building the "correct" cell line model. As a well-established partner for custom cell line engineering, we at MilliporeSigma have encountered many of these challenges and have developed and/or implemented a number of methods to circumvent them. Several of these methods and the new tools available for gene editing will be discussed in this webinar, along with a summary of how they have impacted our internal cell line engineering programs.


 What Will You Learn?

  • Existing bottlenecks in the gene editing process
  • Technology that can be used to overcome specific bottlenecks
  • Ongoing discovery work to streamline gene editing and adapt it to more difficult cell types

 Who Should Attend?

Scientists that are planning to use gene editing to create model cell lines for research and discovery.


Speaker Bio
Mark A. Gerber, Jr., Ph.D.
Principal R&D Scientist, Supervisor, Cell Design Studio
Advanced Genetics and Cellular Technologies
Mark obtained his Ph.D. in Biochemistry and Molecular Biology from Saint Louis University School of Medicine, where he used RNAi in Drosophila models to elucidate developmental and biochemical roles for RNA polymerase II-associated transcription factors. Following graduate school, he was a Postdoctoral Fellow at Washington University in St. Louis, where he investigated signaling pathways involved in the development of human meningioma. Mark joined MilliporeSigma in 2006, and has worked in the areas of biotherapeutic production, stem cell applications, and gene regulation. He currently supervises the Cell Design Studio team, which performs custom cell line engineering for research and pharma markets using ZFN and CRISPR technologies.